Rare success in Alzheimer’s disease research opens hope for future therapies
CHICAGO, Nov 29 (Reuters) – The first big breakthrough in 30 years of Alzheimer’s disease research is giving impetus to clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-stealing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai Co Ltd (4523.T) and Biogen (BIIB.O) announced in September that …
Rare success in Alzheimer’s disease research opens hope for future therapies Read More »